Takeaway

• A new non-hormonal therapy, fezolinetant, reduces the frequency and severity of moderate-to-severe vasomotor symptoms associated with menopause (also called hot flashes or hot flushes) in the phase 3 SKYLIGHT 1 trial.
• The drug also improves quality of life.
• Findings by an international team were reported in The Lancet ....